Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...

Here is a breakdown of the information Valneva Se presented to its investors. Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for ...

Valneva (VALN) has released an update. Valneva SE has reported €116.6 million in total revenues for the first nine months of 2024, with a notable turnaround to a €24.7 million net profit, driven by ...

Nine-Month Key Financial Highlights Total revenues of €116.6 million, including product sales of €112.5 millionNet Profit of €24.7 million, including proceeds from the Priority Review Voucher (PRV)1 ...

The global sales of attenuated vaccines are projected to soar, with an estimated worth of USD 5,068.2 million in 2024 and anticipated to reach USD 9,693.9 million by 2034. This growth trajectory ...

Pfizer has been looking for a fresh start after a rocky 2023, when its stock dropped more than 40% as some of the company's guidance proved overly optimistic. Last October, the company unveiled a cost ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later ...

Valneva Scotland has partnered with Team Jak, a West Lothian-headquartered charity focused on supporting children and young people with cancer. The Livingston-based vaccine producer will provide ...

Valneva (VALN) has released an update. Valneva is set to showcase its pioneering chikungunya vaccine, IXCHIQ®, at several esteemed scientific forums this quarter, highlighting two-year antibody ...

See today's front and back pages, download the newspaper, order back issues and use the historic Daily Express newspaper archive.

Other products accounted for the rest; they were not listed specifically in the Annals report but vaccines sold by Novavax, Sanofi Pasteur, Valneva, and HIPRA, as well as the Russian and Chinese ...